OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017
November 03 2017 - 9:43AM
OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and
financial results for the three and nine months ended September 30,
2017, after the close of the U.S. financial markets on Wednesday,
November 8, 2017.
OPKO’s senior management will provide a business update and
discuss its financial results in a conference call and live audio
webcast beginning at 4:30 p.m. Eastern time on Wednesday, November
8, 2017.
Conference Call & Webcast Information
WHEN: Wednesday, November 8, 2017 at 4:30 p.m. Eastern
time.DOMESTIC DIAL-IN: (866)
634-2258
INTERNATIONAL DIAL-IN: (330)
863-3454 PASSCODE:
8399217WEBCAST: http://investor.opko.com/events.cfm
For those unable to participate in the live conference call or
webcast, a replay will be available beginning November 8, 2017 two
hours after the close of the conference call. To access the replay,
dial (855) 859-2056 or (404) 537-3406. The replay passcode is:
8399217. The replay can be accessed for a period of time on OPKO’s
website at http://investor.opko.com/events.cfm.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to
establish industry leading positions in large, rapidly growing
markets. Our diagnostics business includes BioReference
Laboratories, the nation's third largest clinical laboratory with a
core genetic testing business and a 400 person sales and marketing
team to drive growth and leverage new products, including the
4Kscore® prostate cancer test and the Claros® 1 in office
immunoassay platform. Our pharmaceutical business features
RAYALDEE®, an FDA approved treatment for SHPT in stage 3-4 CKD
patients with vitamin D insufficiency (launched in November 2016),
VARUBI® for chemotherapy induced nausea and vomiting (oral
formulation launched by partner TESARO and IV formulation recently
FDA approved), OPK88003, a once weekly oxyntomodulin for type 2
diabetes and obesity that is a clinically advanced drug candidate
among the new class of GLP-1 glucagon receptor dual agonists, and
OPK88004, a selective androgen receptor modulator being developed
for benign prostatic hyperplasia and other urologic and metabolic
conditions. Our biologics business includes hGH-CTP, a once weekly
human growth hormone injection (in phase 3 and partnered with
Pfizer), and a long acting Factor VIIa drug for hemophilia in phase
2a. We also have production and distribution assets worldwide,
multiple strategic investments and an active business development
strategy. More information is available at www.opko.com.
CONTACTS
CompanyOPKO Health, Inc.David Malina,
305-575-4137dmalina@opko.comDirector of Investor Relations
InvestorsLHA Investor RelationsAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024